Letter to the editor
====================

Plerixafor has been introduced for the mobilization of hematopoietic stem cells to peripheral blood, by interfering with the SDF1-CXCR4 interaction. Although it has been FDA-approved in adult patients with non-Hodgkin lymphoma or multiple myeloma \[[@B1],[@B2]\], the pediatric data usage are scarce, particularly in Asian children \[[@B3]-[@B8]\].

We retrospectively reviewed all 6 patients (3 males, 3 females), who received plerixafor-based mobilization at our center after obtaining the Institutional Review Board approval (H-1108-103-374). They had all previously failed peripheral blood stem cell (PBSC) mobilization by chemotherapy and G-CSF. The patient\'s characteristics, previous treatments and mobilization chemotherapies are shown. (Table [1](#T1){ref-type="table"}) All patients received G-CSF (10 μg/kg) for 4 days, without prior chemotherapy. Then plerixafor (240 μg/kg; Mozobil, Genzyme Inc, Naarden, The Netherlands) and G-CSF (10 μg/kg) were administered subcutaneously, at 10 and 2 hours before each apheresis. CD34^+^cells (median, 11.08 × 10^6^/kg; range, 6.34-28.97 × 10^6^/kg) were mobilized successfully in all patients, after 2 to 3 apheresis without immediate complications (for each apheresis: mean, 6.28 × 10^6^/kg: range, 3.17-14.49 × 10^6^/kg). Seven autologous stem cell transplantations were performed, including 1 tandem transplantation, and the results of engraftment were acceptable. (Table [2](#T2){ref-type="table"})

###### 

Patient Demographics and Prior Treatment Received

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt \#   Dx    Sex   Age   Earlier chemotherapy                                                                                Earlier\       1st line mobilization\
                                                                                                                                radiotherapy   chemotherapy
  ------- ----- ----- ----- --------------------------------------------------------------------------------------------------- -------------- ---------------------------------
  1       NBL   M     11    CDDP + VP16 + ADR + CPM, CPM + Topo + VP16                                                          No             CPM + VP16+ GCSF

  2       MBL   F     11    CDDP + CPM + VCR, CPM + VCR, Carbo + VP16 + IFM + VCR                                               IFRT + CSI     Carbo + VP16 + IFM + VCR + GCSF

  3       OSA   M     6     CDDP + ADR + MTX, IFM + ADR + MTX                                                                   No             CPM + VP16+ GCSF

  4       OSA   F     10    CDDP + ADR + MTX, IFM + ADR + MTX, Gemcitabine + Doxetaxel, CPM + Topo + VP16, IFM + Carbo + VP16   No             CPM + VP16+ GCSF

  5       MBL   M     10    CDDP + CPM + VCR, CPM + VCR                                                                         IFRT + CSI     Carbo + VP16 + IFM + VCR + GCSF

  6       ES    F     15    VCR + ADR + CPM, IFM + VP16                                                                         No             CPM + VP16+ GCSF
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ADR*Doxorubicin, *Carbo*Carboplatin, *CDDP*Cisplatin, *CPM*cyclophosphamide, *CSI*Craniospinal axis irradiation, *ES*Ewing sarcoma, *G-CSF*Granulocyte colony stimulating factor, *IFM*Ifosphamide, *IFRT*Involved field radiation therapy, *LP*Leukapheresis, *MBL*Medulloblastoma, *MTX*Methotrexate, *NBL*Neuroblastoma, *OSA*Osteosarcoma, *Pt*Patient, *Topo*Topotecan, *VCR*Vincristine, *VP16*Etoposide

###### 

PBSC Collection and Engraftment

                 Plerixafor-based PBSC collection           Engraftment                       
  --- ------ --- ---------------------------------- ------- ------------- ----- ------- ----- -----
  1   1.24   4   12.64                              16.13   3             \#1   5.91    10    35
                                                                          \#2   3.48    9     197
  2   0.18   2   9.52                               11.2    2                   4.8     10    26
  3   1.68   2   6.81                               10.67   2                   8.49    10    15
  4   0.7    3   6.34                               15.1    2                   7.04    N/A   N/A
  5   4      4   28.97                              20.25   2                   17.78   10    N/A
  6   0.8    3   15.25                              17.83   2                   3.74    12    18

*ANC*Absolute Neutrophil Count, *LP*Leukapheresis, *N/A*Not Applicable (due to early death), *PBSC*Peripheral Blood Stem Cell, *PLT*Platelet, *Pt*, Patient, *TNC*Total Nuclear Cells, *TPL*Transplantation

Patients \#1, \#3 and \#6 were disease-free at the last follow-up (28, 12 and 3 months after transplantation, respectively), however, patient \#4 died on day 3, due to sudden cardiac arrest. Interestingly, two medulloblastoma patients (patients \#2 and \#5) showed serious lung problems, which include spontaneous pneumomediastinum on day 56 and 11, died on day 102 and 89, respectively. The cause of death of both patients showed to be respiratory failure, of which, the pathogen was not revealed by bronchoalveolar lavage or lung biopsy. The pathologic finding was consistent with a diffuse alveolar damage. In our center, 6 other patients who underwent the same radiotherapy and autologous PBSC transplantation, with the same conditioning regimen, but did not receive plerixafor for mobilization, have not shown such fatal pulmonary complication (data not shown). Due to the plerixafor mobilization of the different cell populations, in comparison with G-CSF alone \[[@B9],[@B10]\], unexpected complications might occur after infusion in susceptible recipients, like the 2 patients that were mentioned above who underwent irradiation around the thoracic area.

In conclusion, we report the first data of Asian pediatric usage of plerixafor for PBSC mobilization, which showed a success rate of 100%, without acute complications. This is a higher success rate than those in the previous pediatric studies \[[@B3],[@B7]\]. However we experienced two patients with medulloblastoma, who suffered from fatal pulmonary complication. Though the pathogenesis was not understood, further studies are needed to investigate possible complications of plerixafor in pediatric patients.
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